<p>Aardvark Therapeutics, Inc. (NASDAQ:AARD - 获取免费报告) 的股价在周五上涨了 12%。该股票最高交易价格为$13.03，最后交易价格为$12.65。在交易过程中，约有 152,066 股易手，较平均每日交易量 186,140 股下降了 18%。该股票之前的收盘价为$11.29。</p>
<p>获取 <strong>Aardvark Therapeutics</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>AARD 已成为多份研究分析师报告的主题。Raymond James Financial 在 1 月 12 日的报告中重申了对 Aardvark Therapeutics 的 &#34;强力买入&#34; 评级，并设定了$47.00 的目标价格。B. Riley Financial 在 1 月 28 日的研究报告中开始覆盖 Aardvark Therapeutics，并设定了 &#34;买入&#34; 评级和$32.00 的目标价格。Cantor Fitzgerald 在 11 月 14 日的报告中重新发布了对 Aardvark Therapeutics 的 &#34;增持&#34; 评级。William Blair 在 12 月 12 日的报告中开始覆盖 Aardvark Therapeutics，并为该公司设定了 &#34;跑赢大盘&#34; 评级。最后，BTIG Research 在 11 月 7 日的研究报告中开始覆盖 Aardvark Therapeutics，并设定了 &#34;买入&#34; 评级和$26.00 的目标价格。一位分析师给予该股票 &#34;强力买入&#34; 评级，十一位给予 &#34;买入&#34; 评级，一位给予 &#34;卖出&#34; 评级。根据 MarketBeat.com 的数据，Aardvark Therapeutics 目前的共识评级为 &#34;适度买入&#34;，共识目标价格为$32.64。</p>
<p><strong>查看我们对 AARD 的最新分析</strong></p>
<h2>Aardvark Therapeutics 股价上涨 12.0%</h2>
<p>该公司的市值为 2.7539 亿美元，市盈率为-5.97。该股票的 50 日移动平均价格为$13.76，200 日移动平均价格为$12.19。</p>
<p>Aardvark Therapeutics (NASDAQ:AARD - 获取免费报告) 最近于 11 月 13 日发布了季度财报。该公司报告季度每股收益为 ($0.75)，超出分析师的共识预期 ($0.82) $0.07。</p>
<h2>内部人士活动</h2>
<p>在其他 Aardvark Therapeutics 的新闻中，首席执行官 Tien-Li Lee 于 12 月 11 日以每股平均价格$14.48 购买了 7,000 股该公司的股票，总价值为$101,360.00。收购后，首席执行官直接持有该公司 1,551,613 股股票，价值约为$22,467,356.24。这笔交易代表其持股比例增加了 0.45%。该交易已在向证券交易委员会的法律文件中披露，文件可通过此链接访问。此外，首席财务官 Nelson Sun 于 12 月 11 日以每股平均价格$14.40 购买了 3,000 股该公司的股票，总交易额为$43,200.00。交易后，首席财务官持有该公司 108,484 股股票，价值约为$1,562,169.60。这代表其持股比例增加了 2.84%。该购买的 SEC 文件提供了更多信息。</p>
<h2>机构投资者对 Aardvark Therapeutics 的看法</h2>
<p>几家机构投资者最近对 AARD 的持仓进行了调整。Two Sigma Investments LP 在第三季度收购了 Aardvark Therapeutics 的新股份，价值$845,000。Bridgeway Capital Management LLC 在第三季度购买了 Aardvark Therapeutics 的新股份，价值约$292,000。瑞银集团在第三季度将其在 Aardvark Therapeutics 的股份增加了 5.4%。瑞银集团目前拥有 54,728 股该公司的股票，价值$727,000，在上个季度又购买了 2,804 股。法国巴黎银行金融市场在第三季度将其在 Aardvark Therapeutics 的股份增加了 59.3%。法国巴黎银行金融市场目前拥有 56,546 股该公司的股票，价值$751,000，在上个季度又购买了 21,052 股。最后，美国银行在第二季度将其在 Aardvark Therapeutics 的持股增加了 72.9%。美国银行目前拥有 7,989 股该公司的股票，价值$108,000，在此期间又购买了 3,369 股。</p>
<h2>Aardvark Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Aardvark Therapeutics, Inc 是一家位于马萨诸塞州剑桥的临床阶段生物制药公司，专注于小分子调节剂的发现和开发，这些调节剂作用于视黄酸受体相关孤儿受体伽马 (RORγ)。RORγ 在 T 辅助 17 (Th17) 细胞分化和炎症过程中发挥核心作用。通过靶向这一转录因子，Aardvark 旨在解决一系列自身免疫和免疫介导的疾病。</p>
<p>该公司的主要项目包括选择性 RORγ 反向激动剂，旨在抑制在银屑病、炎症性肠病和其他慢性炎症疾病等情况下由 Th17 驱动的病理反应。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Aardvark Therapeutics</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>~$1.5T SpaceX IPO：首次公开募股机会</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>在东部时间上午 9:30 到 10:45 之间进行交易</li>
<li>何时购买黄金（从数学角度）</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Aardvark Therapeutics 吗？</h2>
<p>在考虑 Aardvark Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Aardvark Therapeutics 并不在名单上。</p>
<p>虽然 Aardvark Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AARD

<p>Aardvark Therapeutics (NASDAQ:AARD) 的股价上涨了 12%，达到 12.65 美元，市值为 2.7539 亿美元。分析师给予的共识评级为 “适度买入”，目标价为 32.64 美元。最近的内部交易包括首席执行官 Tien-Li Lee 购买了 7,000 股，首席财务官 Nelson Sun 购买了 3,000 股。机构投资者也增加了对公司的持股。Aardvark 专注于开发针对自身免疫疾病的小分子调节剂，其主要项目针对 Th17 驱动的疾病</p>

<p>Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report)'s share price rose 12% on Friday . The stock traded as high as $13.03 and last traded at $12.65. Approximately 152,066 shares changed hands during trading, a decline of 18% from the average daily volume of 186,140 shares. The stock had previously closed at $11.29.</p>
<div class="lb-trans"><p>Aardvark Therapeutics, Inc. (NASDAQ:AARD - 获取免费报告) 的股价在周五上涨了 12%。该股票最高交易价格为$13.03，最后交易价格为$12.65。在交易过程中，约有 152,066 股易手，较平均每日交易量 186,140 股下降了 18%。该股票之前的收盘价为$11.29。</p>
</div><p>Get <strong>Aardvark Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aardvark Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>AARD has been the subject of a number of research analyst reports. Raymond James Financial reiterated a &#34;strong-buy&#34; rating and set a $47.00 price target on shares of Aardvark Therapeutics in a report on Monday, January 12th. B. Riley Financial started coverage on Aardvark Therapeutics in a research note on Wednesday, January 28th. They set a &#34;buy&#34; rating and a $32.00 target price for the company. Cantor Fitzgerald reissued an &#34;overweight&#34; rating on shares of Aardvark Therapeutics in a report on Friday, November 14th. William Blair started coverage on Aardvark Therapeutics in a report on Friday, December 12th. They set an &#34;outperform&#34; rating for the company. Finally, BTIG Research initiated coverage on shares of Aardvark Therapeutics in a research report on Friday, November 7th. They set a &#34;buy&#34; rating and a $26.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Aardvark Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $32.64.</p>
<div class="lb-trans"><p>AARD 已成为多份研究分析师报告的主题。Raymond James Financial 在 1 月 12 日的报告中重申了对 Aardvark Therapeutics 的 &#34;强力买入&#34; 评级，并设定了$47.00 的目标价格。B. Riley Financial 在 1 月 28 日的研究报告中开始覆盖 Aardvark Therapeutics，并设定了 &#34;买入&#34; 评级和$32.00 的目标价格。Cantor Fitzgerald 在 11 月 14 日的报告中重新发布了对 Aardvark Therapeutics 的 &#34;增持&#34; 评级。William Blair 在 12 月 12 日的报告中开始覆盖 Aardvark Therapeutics，并为该公司设定了 &#34;跑赢大盘&#34; 评级。最后，BTIG Research 在 11 月 7 日的研究报告中开始覆盖 Aardvark Therapeutics，并设定了 &#34;买入&#34; 评级和$26.00 的目标价格。一位分析师给予该股票 &#34;强力买入&#34; 评级，十一位给予 &#34;买入&#34; 评级，一位给予 &#34;卖出&#34; 评级。根据 MarketBeat.com 的数据，Aardvark Therapeutics 目前的共识评级为 &#34;适度买入&#34;，共识目标价格为$32.64。</p>
</div><p><strong>Check Out Our Latest Analysis on AARD</strong></p>
<div class="lb-trans"><p><strong>查看我们对 AARD 的最新分析</strong></p>
</div><h2>Aardvark Therapeutics Stock Up 12.0%</h2>
<div class="lb-trans"><h2>Aardvark Therapeutics 股价上涨 12.0%</h2>
</div><p>The company has a market cap of $275.39 million and a P/E ratio of -5.97. The stock has a 50 day moving average price of $13.76 and a two-hundred day moving average price of $12.19.</p>
<div class="lb-trans"><p>该公司的市值为 2.7539 亿美元，市盈率为-5.97。该股票的 50 日移动平均价格为$13.76，200 日移动平均价格为$12.19。</p>
</div><p>Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.75) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.07.</p>
<div class="lb-trans"><p>Aardvark Therapeutics (NASDAQ:AARD - 获取免费报告) 最近于 11 月 13 日发布了季度财报。该公司报告季度每股收益为 ($0.75)，超出分析师的共识预期 ($0.82) $0.07。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部人士活动</h2>
</div><p>In other Aardvark Therapeutics news, CEO Tien-Li Lee acquired 7,000 shares of the business's stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $14.48 per share, with a total value of $101,360.00. Following the acquisition, the chief executive officer directly owned 1,551,613 shares of the company's stock, valued at approximately $22,467,356.24. This trade represents a 0.45% increase in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, CFO Nelson Sun bought 3,000 shares of the firm's stock in a transaction on Thursday, December 11th. The shares were acquired at an average price of $14.40 per share, for a total transaction of $43,200.00. Following the transaction, the chief financial officer owned 108,484 shares in the company, valued at approximately $1,562,169.60. This represents a 2.84% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.</p>
<div class="lb-trans"><p>在其他 Aardvark Therapeutics 的新闻中，首席执行官 Tien-Li Lee 于 12 月 11 日以每股平均价格$14.48 购买了 7,000 股该公司的股票，总价值为$101,360.00。收购后，首席执行官直接持有该公司 1,551,613 股股票，价值约为$22,467,356.24。这笔交易代表其持股比例增加了 0.45%。该交易已在向证券交易委员会的法律文件中披露，文件可通过此链接访问。此外，首席财务官 Nelson Sun 于 12 月 11 日以每股平均价格$14.40 购买了 3,000 股该公司的股票，总交易额为$43,200.00。交易后，首席财务官持有该公司 108,484 股股票，价值约为$1,562,169.60。这代表其持股比例增加了 2.84%。该购买的 SEC 文件提供了更多信息。</p>
</div><h2>Institutional Investors Weigh In On Aardvark Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Aardvark Therapeutics 的看法</h2>
</div><p>Several institutional investors have recently made changes to their positions in AARD. Two Sigma Investments LP acquired a new stake in shares of Aardvark Therapeutics during the 3rd quarter worth $845,000. Bridgeway Capital Management LLC bought a new stake in Aardvark Therapeutics during the third quarter worth about $292,000. UBS Group AG grew its stake in Aardvark Therapeutics by 5.4% during the third quarter. UBS Group AG now owns 54,728 shares of the company's stock worth $727,000 after buying an additional 2,804 shares in the last quarter. BNP Paribas Financial Markets grew its stake in Aardvark Therapeutics by 59.3% during the third quarter. BNP Paribas Financial Markets now owns 56,546 shares of the company's stock worth $751,000 after buying an additional 21,052 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in Aardvark Therapeutics by 72.9% in the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company's stock valued at $108,000 after buying an additional 3,369 shares during the period.</p>
<div class="lb-trans"><p>几家机构投资者最近对 AARD 的持仓进行了调整。Two Sigma Investments LP 在第三季度收购了 Aardvark Therapeutics 的新股份，价值$845,000。Bridgeway Capital Management LLC 在第三季度购买了 Aardvark Therapeutics 的新股份，价值约$292,000。瑞银集团在第三季度将其在 Aardvark Therapeutics 的股份增加了 5.4%。瑞银集团目前拥有 54,728 股该公司的股票，价值$727,000，在上个季度又购买了 2,804 股。法国巴黎银行金融市场在第三季度将其在 Aardvark Therapeutics 的股份增加了 59.3%。法国巴黎银行金融市场目前拥有 56,546 股该公司的股票，价值$751,000，在上个季度又购买了 21,052 股。最后，美国银行在第二季度将其在 Aardvark Therapeutics 的持股增加了 72.9%。美国银行目前拥有 7,989 股该公司的股票，价值$108,000，在此期间又购买了 3,369 股。</p>
</div><h2>Aardvark Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Aardvark Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.</p>
<div class="lb-trans"><p>Aardvark Therapeutics, Inc 是一家位于马萨诸塞州剑桥的临床阶段生物制药公司，专注于小分子调节剂的发现和开发，这些调节剂作用于视黄酸受体相关孤儿受体伽马 (RORγ)。RORγ 在 T 辅助 17 (Th17) 细胞分化和炎症过程中发挥核心作用。通过靶向这一转录因子，Aardvark 旨在解决一系列自身免疫和免疫介导的疾病。</p>
</div><p>The company's lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.</p>
<div class="lb-trans"><p>该公司的主要项目包括选择性 RORγ 反向激动剂，旨在抑制在银屑病、炎症性肠病和其他慢性炎症疾病等情况下由 Th17 驱动的病理反应。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Aardvark Therapeutics</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Trade this between 9:30 and 10:45 am EST</li>
<li>When to buy gold (mathematically)</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Aardvark Therapeutics</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>~$1.5T SpaceX IPO：首次公开募股机会</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>在东部时间上午 9:30 到 10:45 之间进行交易</li>
<li>何时购买黄金（从数学角度）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aardvark Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Aardvark Therapeutics 吗？</h2>
</div><p>Before you consider Aardvark Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Aardvark Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aardvark Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Aardvark Therapeutics 并不在名单上。</p>
</div><p>While Aardvark Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aardvark Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Aardvark Therapeutics（NASDAQ:AARD）股价上涨 12% - 现在是买入的好时机吗？